



Pharmacovigilance: Partnering for Patient Safety

November 20th 2012 10.30 to 12.00
Restaurant Vieux-Bois (Salon Dunant)
Avenue de la Paix 12, Geneva

Registration and welcome coffee from 10.00

Lunch beginning at 12.00pm

Pharmacovigilance is defined by the World Health Organization (WHO) as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems”.

This Geneva Pharma Forum aims at highlighting the key role that pharmacovigilance systems play in identifying potential risk factors and in guaranteeing patient safety worldwide. The speakers will guide the audience through the commitment and work of the international organizations in promoting adequate pharmacovigilance, with a specific focus on biotherapeutic medicines.

Please RSVP to:

Martina Bilova, IFPMA, Tel +41/22 338 3200

m.bilova@ifpma.org

Programme

Moderator

Dr. Otmar Kloiber
Secretary General
World Medical Association

10.30 – 10.35

Introduction & Welcome
IFPMA

Presentations

10.35 – 10.55

Dr. Shanthi Pal
Programme Manager for Pharmacovigilance
Quality Assurance and Safety of Medicines,
World Health Organization

10.55 – 11.15

Dr. Fermin Ruiz de Erenchun
IFPMA Biotherapeutics Group Chair
(F. Hoffmann-La Roche)

11.15 – 11.35

Dr. Jeremiah Mwangi
Policy and External Affairs Director
International Alliance of Patients' Organizations

Moderated panel discussion and Q&A

11.35 – 12.00

